ESALY Stock UPDATES Eisai Co Ltd Spons A (ESALY) 42.7600 08/03/2014
Post# of 273389
Posted On: 08/03/2014 4:22:11 PM
Eisai Co Ltd Spons A (ESALY) 42.7600 $ESALY
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
JCN Newswire - Wed Jul 30, 9:48PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate ("lenvatinib" in the treatment of radioiodine-refractory differentiated thyroid cancer.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy
JCN Newswire - Thu Jul 03, 7:58PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.
Eisai to Launch First Chocola BB Brand Product "Chocola BB Royal Drink" in China
JCN Newswire - Wed Jul 02, 5:46AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has launched its Chocola BB Royal Drink in China. This marks the first Chocola BB series product launched in China by Eisai.
Orexigen falls on further FDA delays for diet pill
By The Associated Press - AP - Wed Jun 11, 11:58AM CDT
Shares of Orexigen Therapeutics tumbled more than 16 percent in afternoon trading Wednesday after regulators extended by three months a review of its experimental weight loss treatment.
Does Wall Street Still Hate Arena Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Mon Jun 09, 5:00PM CDT
It's no secret that Wall Street has been betting heavily against Arena Pharmaceuticals , both before and after the Food and Drug Administration approved the company's fat-fighting pill, Belviq. The investing thesis is simple and to the point:...
Is Arena or VIVUS the Better Obesity Drug Stock?
Leo Sun, The Motley Fool - Motley Fool - Sat May 31, 12:30PM CDT
Investors had high hopes for Arena 's Belviq and VIVUS ' Qsymia when in 2012 they became the first new obesity drugs in 13 years to receive FDA approval. Yet by looking at how Arena and VIVUS have...
Eisai Honored with Prestigious 'UCL Enterprise Partner Of The Year 2014' Award By University College London (UCL)
JCN Newswire - Fri May 30, 12:24AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai" and University College London (UCL) announced today that Eisai has been awarded the coveted 'UCL Enterprise Partner of the Year 2014' accolade at the 7th annual UCL Awards for Enterprise held last night in London, UK.
Antiemetic Agent Aloxi Approved for Children by the U.S. FDA
JCN Newswire - Thu May 29, 5:27AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai" announced today that the antiemetic agent ALOXI (generic name: palonosetron HCI) has been approved in the U.S. for an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to up to 17 years by the U.S. Food and Drug Administration (FDA). Despite peak cancer incidence among children occurring within the first year of life, this is the first product for chemotherapy-induced nausea and vomiting (CINV) prevention approved in patients aged between 1 and 6 months after birth. Eisai's U.S subsidiary Eisai Inc. markets this product based on having received exclusive marketing rights from Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland) for the U.S.
Eisai Receives Positive Opinion from EMA's CHMP on Expanding
JCN Newswire - Tue May 27, 2:04AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai" announced today that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier-line treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.
Eisai to Launch Chocola BB Sparkling Salty Natsumikan Flavor
JCN Newswire - Tue May 27, 1:15AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai" announced today that it will launch its new carbonated supplement drink Chocola BB Sparkling Salty Natsumikan* Flavor, classified as a Food with Nutrient Function Claims, in Japan on Monday, June 2.
Eisai's R&D Subsidiary Kan Research Institute Commences Full-Scale Operation at New Facility
JCN Newswire - Mon May 26, 3:32AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai" announced that its research and development subsidiary KAN Research Institute, Inc. (Headquarters: Hyogo Prefecture, President & CEO: Toshio Imai, "KRI" held a dedication ceremony today for its new research facility in Kobe, Hyogo prefecture, and has now officially commenced full-scale operation of its research and development activities at this facility.
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
JCN Newswire - Wed Jul 30, 9:48PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate ("lenvatinib" in the treatment of radioiodine-refractory differentiated thyroid cancer. Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy
JCN Newswire - Thu Jul 03, 7:58PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. Eisai to Launch First Chocola BB Brand Product "Chocola BB Royal Drink" in China
JCN Newswire - Wed Jul 02, 5:46AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has launched its Chocola BB Royal Drink in China. This marks the first Chocola BB series product launched in China by Eisai. Orexigen falls on further FDA delays for diet pill
By The Associated Press - AP - Wed Jun 11, 11:58AM CDT
Shares of Orexigen Therapeutics tumbled more than 16 percent in afternoon trading Wednesday after regulators extended by three months a review of its experimental weight loss treatment.
Does Wall Street Still Hate Arena Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Mon Jun 09, 5:00PM CDT
It's no secret that Wall Street has been betting heavily against Arena Pharmaceuticals , both before and after the Food and Drug Administration approved the company's fat-fighting pill, Belviq. The investing thesis is simple and to the point:...
Is Arena or VIVUS the Better Obesity Drug Stock?
Leo Sun, The Motley Fool - Motley Fool - Sat May 31, 12:30PM CDT
Investors had high hopes for Arena 's Belviq and VIVUS ' Qsymia when in 2012 they became the first new obesity drugs in 13 years to receive FDA approval. Yet by looking at how Arena and VIVUS have...
Eisai Honored with Prestigious 'UCL Enterprise Partner Of The Year 2014' Award By University College London (UCL)
JCN Newswire - Fri May 30, 12:24AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"
and University College London (UCL) announced today that Eisai has been awarded the coveted 'UCL Enterprise Partner of the Year 2014' accolade at the 7th annual UCL Awards for Enterprise held last night in London, UK. Antiemetic Agent Aloxi Approved for Children by the U.S. FDA
JCN Newswire - Thu May 29, 5:27AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"
announced today that the antiemetic agent ALOXI (generic name: palonosetron HCI) has been approved in the U.S. for an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to up to 17 years by the U.S. Food and Drug Administration (FDA). Despite peak cancer incidence among children occurring within the first year of life, this is the first product for chemotherapy-induced nausea and vomiting (CINV) prevention approved in patients aged between 1 and 6 months after birth. Eisai's U.S subsidiary Eisai Inc. markets this product based on having received exclusive marketing rights from Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland) for the U.S. Eisai Receives Positive Opinion from EMA's CHMP on Expanding
JCN Newswire - Tue May 27, 2:04AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"
announced today that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier-line treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. Eisai to Launch Chocola BB Sparkling Salty Natsumikan Flavor
JCN Newswire - Tue May 27, 1:15AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"
announced today that it will launch its new carbonated supplement drink Chocola BB Sparkling Salty Natsumikan* Flavor, classified as a Food with Nutrient Function Claims, in Japan on Monday, June 2. Eisai's R&D Subsidiary Kan Research Institute Commences Full-Scale Operation at New Facility
JCN Newswire - Mon May 26, 3:32AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"
announced that its research and development subsidiary KAN Research Institute, Inc. (Headquarters: Hyogo Prefecture, President & CEO: Toshio Imai, "KRI" held a dedication ceremony today for its new research facility in Kobe, Hyogo prefecture, and has now officially commenced full-scale operation of its research and development activities at this facility. Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
(0)
(0)